07:47 AM EDT, 03/19/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday that Health Canada has approved Keytruda combined with chemotherapy for adults with advanced or recurrent endometrial cancer.

The decision is based on the results of a late-stage trial that showed Keytruda combined with carboplatin and paclitaxel helped delay disease progression in both major patient groups with mismatch repair-deficient and proficient tumors, the company said.